2011
Breast Medical Oncologists' Use of Standard Prognostic Factors to Predict a 21‐Gene Recurrence Score
Kamal AH, Loprinzi CL, Reynolds C, Dueck AC, Geiger XJ, Ingle JN, Carlson RW, Hobday TJ, Winer EP, Goetz MP. Breast Medical Oncologists' Use of Standard Prognostic Factors to Predict a 21‐Gene Recurrence Score. The Oncologist 2011, 16: 1359-1366. PMID: 21934103, PMCID: PMC3228065, DOI: 10.1634/theoncologist.2011-0048.Peer-Reviewed Original ResearchConceptsRecurrence scorePrognostic criteriaRS riskTreatment recommendationsIntermediate-risk casesHormone receptor statusLymph node negativeProspective clinical trialsStandard prognostic factorsIntermediate recurrence scoreAbility of oncologistsChemotherapy useChemotherapy recommendationsChemotherapy benefitNode negativePrognostic factorsReceptor statusHistologic typeAcademic oncologistsOncologists' useTumor gradeClinical trialsBreast cancerRS categoryOncologist's ability
2008
Self-Reported Practices and Attitudes of US Oncologists Regarding Off-Protocol Therapy
Peppercorn J, Burstein H, Miller FG, Winer E, Joffe S. Self-Reported Practices and Attitudes of US Oncologists Regarding Off-Protocol Therapy. Journal Of Clinical Oncology 2008, 26: 5994-6000. PMID: 19029413, DOI: 10.1200/jco.2008.18.1420.Peer-Reviewed Original ResearchConceptsUS oncologistsInvestigational cancer therapiesUS medical oncologistsSelf-reported practicesAdjuvant trastuzumabCommunity oncologistsMedical oncologistsOpen trialAcademic oncologistsClinical trialsTrial recruitmentOncologistsClinical issuesDevelopment of guidelinesInformed consentLack of consensusAnonymous surveyCancer therapyTrialsPatientsTherapyDemographic factorsRandom sampleMonthsFurther definition
2007
How well do standard prognostic criteria predict oncotype DX (ODX) scores?
Kamal A, Loprinzi C, Reynolds C, Dueck A, Geiger X, Ingle J, Carlson R, Hobday T, Winer E, Perez E, Goetz M. How well do standard prognostic criteria predict oncotype DX (ODX) scores? Journal Of Clinical Oncology 2007, 25: 576-576. DOI: 10.1200/jco.2007.25.18_suppl.576.Peer-Reviewed Original ResearchODX scoresPrognostic criteriaBreast cancerExpert breast pathologistsMayo Clinic patientsOncotype DX scoreAssessment of ERAdjuvant chemotherapyIntermediate riskBreast pathologistsClinic patientsTumor sizeAcademic oncologistsTumor gradeHigh riskTumor slidesStandardized criteriaClinical casesPatientsOncologistsGene expression profilingSignificant financial relationshipChemotherapyODXScores
2006
Use of experimental therapy outside of clinical trials among U.S. oncologists
Peppercorn J, Joffe S, Burstein H, Winer E. Use of experimental therapy outside of clinical trials among U.S. oncologists. Journal Of Clinical Oncology 2006, 24: 6047-6047. DOI: 10.1200/jco.2006.24.18_suppl.6047.Peer-Reviewed Original ResearchClinical trialsPractice settingsInvestigational cancer therapiesAttitudes of physiciansDemographic factorsU.S. oncologistsCommunity oncologistsMedical oncologistsTrial enrollmentAcademic oncologistsRecent trialsExperimental therapiesPatient's requestAmerican oncologistsOncology communityGuideline developmentOncologistsPatientsSignificant financial relationshipTrialsMonthsCancer therapyTherapyRandom sampleCare